1409 related articles for article (PubMed ID: 31693429)
21. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
Am J Hematol; 2024 Jul; 99(7):1281-1289. PubMed ID: 38700035
[TBL] [Abstract][Full Text] [Related]
22. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
[No Abstract] [Full Text] [Related]
23. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
25. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
26. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
27. A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma.
Liu Y; Wuxiao Z; Kong F; Feng J; Wu J; Yao Z; Zhou W; Li F
Ann Transl Med; 2022 Oct; 10(19):1070. PubMed ID: 36330404
[TBL] [Abstract][Full Text] [Related]
28. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
29. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Smith SD; Lopedote P; Samara Y; Mei M; Herrera AF; Winter AM; Hill BT; Shadman M; Ujjani C; Lynch RC; Jacobson CA; Kim AI; Caimi P; Milano F; Gopal AK
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):170-175. PubMed ID: 33431309
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
[TBL] [Abstract][Full Text] [Related]
31. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
[TBL] [Abstract][Full Text] [Related]
32. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
33. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
34. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
[TBL] [Abstract][Full Text] [Related]
35. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Camus V; Tilly H
Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
[TBL] [Abstract][Full Text] [Related]
36. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K
Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
Kawasaki N; Tomita M; Yamashita-Kashima Y; Yoshimura Y; Yoshiura S
Leuk Lymphoma; 2023 Dec; 64(12):1938-1948. PubMed ID: 37548343
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of polatuzumab-bendamustine-rituximab
Calamia M; McBride A; Abraham I
J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
[TBL] [Abstract][Full Text] [Related]
39. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N; Duell J; Fitzgerald D; Kerkhoff A; Noerenberg D; Kaebisch E; Acker F; Fuhrmann S; Leng C; Welslau M; Chemnitz J; Middeke JM; Weber T; Holtick U; Trappe R; Pfannes R; Liersch R; Spoer C; Fuxius S; Gebauer N; Caillé L; Geer T; Koenecke C; Keller U; Claus R; Mougiakakos D; Mayer S; Huettmann A; Pott C; Trummer A; Wulf G; Brunnberg U; Bullinger L; Hess G; Mueller-Tidow C; Glass B; Lenz G; Dreger P; Dietrich S
Blood Adv; 2021 Jul; 5(13):2707-2716. PubMed ID: 34196677
[TBL] [Abstract][Full Text] [Related]
40. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE; Olszewski AJ; Assouline S; Lossos IS; Diefenbach C; Kamdar M; Ghosh N; Modi D; Sabry W; Naik S; Mehta A; Nakhoda SK; Smith SD; Dorritie K; Jia T; Pham S; Huw LY; Jing J; Wu H; Ead WS; To I; Batlevi CL; Wei MC; Chavez JC
Nat Med; 2024 Jan; 30(1):229-239. PubMed ID: 38072960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]